RT Journal Article SR Electronic T1 Logistics of Adopting 177Lu-Vipivotide Tetraxetan Therapy in a Community-Based Hospital Setting JF Journal of Nuclear Medicine Technology JO J. Nucl. Med. Technol. FD Society of Nuclear Medicine SP 68 OP 71 DO 10.2967/jnmt.124.268039 VO 53 IS 1 A1 Marsh, Kathleen A1 Allickson, Kayla A1 Jesz, Amanda A1 Hanson, Cheryl A1 Newman, Donna A1 Martin-Macintosh, Erica YR 2025 UL http://tech.snmjournals.org/content/53/1/68.abstract AB Prostate cancer is a leading cause of cancer death in men. Advanced disease may progress to metastatic castration-resistant prostate cancer. In March 2022, 177Lu-vipivotide tetraxetan was U.S. Food and Drug Administration–approved for patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have previously received other therapies, including androgen deprivation and taxane therapies. Methods: Although preliminary data for 177Lu-vipivotide tetraxetan has shown extension of overall survival of patients, there is little literature about realistically initiating 177Lu-vipivotide tetraxetan into non–academic-based clinical practices. Results: This article presents a multidisciplinary practice implementation workflow for 177Lu-vipivotide tetraxetan. It also highlights the challenges and considerations for initiating such a theranostics practice. Conclusion: The aim of this work is to help nontertiary medical centers improve patient accessibility for beneficial radiopharmaceutical therapies, specifically 177Lu-vipivotide tetraxetan.